期刊
NATURE REVIEWS RHEUMATOLOGY
卷 18, 期 11, 页码 641-656出版社
NATURE PORTFOLIO
DOI: 10.1038/s41584-022-00841-0
关键词
-
类别
Immune-checkpoint inhibitors (ICIs) have changed the management of advanced cancers and have shown promising efficacy. However, they can also cause immune-related adverse events (irAEs), which pose safety risks. The use of ICIs in patients with pre-existing autoimmune disease is an area of increasing interest, and there is accumulating evidence suggesting acceptable safety profile in this population. Balancing immune suppression and anti-tumor immune response remains a challenge in clinical practice.
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of advanced cancers. Designed to enhance the antitumour immune response, they can also cause off-target immune-related adverse events (irAEs), which are sometimes severe. Although the efficacy of ICIs suggests that they could have wide-ranging benefits, clinical trials of the drugs have so far excluded patients with pre-existing autoimmune disease. However, evidence is accumulating with regard to the use of ICIs in this 'at-risk' population, with retrospective data suggesting that they have an acceptable safety profile, but that there is a risk of disease flare or other irAE occurrence. The management of immunosuppressive drugs at ICI initiation in patients with autoimmune disease (or later in instances of disease flare or irAE) remains a question of particular interest in clinical practice, in which there is always a search for the balance between protecting against autoimmunity and ensuring a good tumour response. Although temporary use of immunosuppressants seems safe, prolonged use or use at ICI initiation might hamper the antitumour immune response, prompting clinicians to use the minimal efficient immunosuppressive regimen. However, a new paradigm is emerging, in which inhibitors of TNF or IL-6 could have synergistic effects with ICIs on tumour response, while also preventing severe irAEs. If confirmed, this 'decoupling' effect on toxicity and efficacy could change therapeutic practice in this field. Knowledge of the current use of ICIs in patients with pre-existing autoimmune disease, particularly with regard to the use of immunosuppressive drugs and/or biologic DMARDs, can help to guide clinical practice. In this Review, the authors discuss the use of immune-checkpoint inhibitors for treatment of cancer in patients with pre-existing autoimmune disease, including the possibility of the use of biologic DMARDs to enhance tumour responses while preventing severe immune-related adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据